Synthesis, complex stability and small animal PET imaging of a novel 64Cu-labelled cryptand molecule by Foerster, Christian et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis, complex stability and small animal PET 
imaging of a novel 
64
Cu-labelled cryptand 
molecule† 
 
Christian Foerster,
a
 James C. Knight,
a
 Melinda Wuest,
a
 Brendan Rowan,
b
 
Suzanne E. Lapi,
c
 Angelo J. Amoroso,
b
 Peter G. Edwards
b
 and Frank Wuest*
a 
 
The radiosynthesis and radiopharmacological evaluation including small animal PET imaging of a novel 
64Cu-labelled cryptand molecule ([64Cu]CryptTM) possessing a tris-pyridyl/tris-amido set of donor atoms is 
described. 
 
 
 
Positron emission tomography (PET) is a rapidly expanding non-
invasive molecular imaging methodology which allows high 
sensitivity mapping of biochemical and physiological processes at 
the cellular and molecular level in vivo.1 An important aspect in the 
success of this technique is the use of suitably designed radiolabelled 
molecular probes, also referred to as PET radiotracers.2–5 Whilst the 
most prevalent PET radio-tracer in clinical practice is 2-[
18
F] uoro-
2-deoxy-D-glucose ([
18
F] FDG) for measuring glucose metabolic 
rate, other radiotracers like proliferation marker [
18
F] uorothymidine 
([
18
F]FLT), hypoxia imaging agent [
18
F] uoromisonidazole 
([
18
F]FMISO) and amino acid metabolism marker [
11
C]methionine 
([
11
C]-MET) have become clinically highly relevant PET 
radiotracers for various applications in oncology, neurology, and 
cardi-ology.1,5 The majority of PET radiotracers in clinical use 
contain short-lived positron emitters carbon-11 (
11
C, t1/2 ¼ 20.4 
min) and uorine-18 (
18
F, t1/2 ¼ 109.8 min).
4 The short half-lives of 
11
C and 
18
F make these radionuclides well-suited for radio-labelling 
small molecules as exempli ed by PET radiotracers like [
18
F]FDG, 
[
18
F]FLT, [
18
F]FMISO, and [
11
C]MET. In contrast, higher 
molecular weight compounds like proteins (e.g. anti-bodies) and 
nanoparticles for molecular imaging and radio-therapy purposes 
require PET radionuclides with longer physical half-lives to 
accommodate the longer residence times of these larger constructs in 
the circulation.6–9  
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The PET radiometal copper-64 (
64
Cu, t1/2 ¼ 12.7 h) has been the 
subject of intensive research eﬀorts for the development of both 
diagnostic PET radiotracers and radiotherapeutics.10,11 Prominent 
examples include hypoxia and perfusion imaging agents such as 
[
64
Cu]Cu-ATSM, [
64
Cu]Cu-PTSM, and [
64
Cu]Cu- 
 
MTUBo respectively.  
64
Cu as a radiometal for molecular The application of 
imaging and radiotherapy requires the use of chelating 
agents to form kinetically inert and thermodynamically stable 
complexes.15 High complex stability is needed to obviate hydrolysis 
and trans-chelation to copper chelating proteins like ceruloplasmin, 
superoxide dismutase (SOD), metallothioneins, and copper 
transporting ATPases.16–18 Many applications utilise bifunctional 
chelators (BFCs) to sequester the [
64
Cu]Cu
2+
 cation within a 
thermodynamically stable and kinetically inert framework while 
allowing attachment to selected targeting vectors (e.g. peptides, 
proteins). Popular and widely used BFCs for [
64
Cu]Cu
2+
 
complexation include macrocyclic chelators like 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-
triazacyclononane-N,N
0
,N
00
-triacetic acid (NOTA), and cross-
ridged macrocycles like CB-TE2A.8,19–21 Within the class of 
macrocyclic chelators, cryptand molecules have been considered as 
particularly suitable ligands for their strong binding of Cu
2+
 cations 
and the kinetic inertness of the result-ing complexes. Cryptands (a 
term derived from the greek krypt¯e, meaning hidden) are ligands 
which ‘entomb’ metal ions like Cu
2+
 within a macrobicyclic 
framework. The result is o en a metal complex with extraordinary 
thermodynamic and kinetic  
 
 
 
 
 
 
 
 
 
Fig. 1 Examples of Sar-type cryptands derived from sarcophagine. 
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stability.22 Prominent examples are cryptands derived from sarcophagine 
(Sar) such as DiAmSar and SarAr (Fig. 1), which form robust complexes 
(cryptates) with [
64
Cu]Cu
2+
 that are 
 
highly resistant towards transchelation. 
 
While the Sar-based cryptands oﬀ er 
excellent Cu
2+
 chelating properties, the 
challenging synthetic route to obtain bifunc-tional Sar derivatives 
has undoubtedly hampered their wider application within the 
imaging community. 
 
Given the remarkably limited number of examples of crypt-ands 
employed for in vivo imaging applications, and consid-ering the 
potential of cryptand frameworks to improve overall imaging 
performance with radiometal complexes, we have evaluated the 
cryptand molecule CryptTM as novel chelating agent for 
[
64
Cu]Cu
2+
 (Fig. 2). Cryptand CryptTM was prepared in good 
chemical yields via an elegant Pd-catalysed carbonylation reaction 
starting from readily available tris-aminoethylamine and tris(3-
bromo-2-pyridyl)methanol. In this previous study, the crystal 
structure of the copper complex with CrypTM revealed coordination 
of the Cu
2+
 ion to one side of the cryptand in a slightly distorted 
square planar coordination sphere.25 CrypTM is doubly 
deprotonated, and the N4-coordination sphere of the Cu
2+
 ion 
involved two pyridyl and two amido N-donors. Protonation of the 
tertiary amine resulted in an overall 1+ charge of the Cu(II)-cryptate. 
Based on this intriguing nding, we now report the radiosynthesis and 
rst radio-pharmacological evaluation of [
64
Cu]Cu–CryptTM 
complex. Radiopharmacology with [
64
Cu]Cu–CryptTM involved 
challenge experiments with competitive chelators EDTA (ethyl-
enediaminetetraacetic acid) and NOTA to assess complex stability in 
vitro, as well as small animal PET studies in mice to assess the 
biodistribution pro le in comparison with another, literature-reported 
copper-cryptate [
64
Cu]Cu–DiAmSar. The radiosynthesis and 
proposed structure of [
64
Cu]Cu–CryptTM is depicted in Fig. 2. 
 
 
In order to optimise the 
64
Cu complexation procedure, we 
explored the impact of various reaction conditions on radio-labelling 
yield and subsequent speci c activity of [
64
Cu]Cu– CryptTM. This 
involved systematically altering (i) the concen-tration of CryptTM, 
(ii) type and volume of buﬀ er solution, (iii) radioactivity 
concentration cA of [
64
Cu]Cu(OAc)2 in 100 mM ammonium acetate 
buﬀ er (pH 5.5), and (iv) reaction tempera-ture. The results 
(summarised in Table 1) clearly indicate the importance of CryptTM 
concentration, radioactivity concentra-tion and reaction temperature 
on obtained radiochemical yield 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Radiosynthesis of [64Cu]Cu–CryptTM. 
 
and speci c activity. Using low concentrations of CryptTM resulted 
in only moderate radiochemical yields in the range of 51–64% and 
low speci c activities (entry 1). Increasing the CryptTM 
concentration up to 0.34 nmol mL 
1
 gave higher radiochemical 
yields of 78% at 25 C. 
 
Performance of the reaction at 37 C further increased the 
radiochemical yield to 95% which suggests that complexation of 
CryptTM with [
64
Cu]Cu
2+
 is a kinetically driven reaction (entries 2–
7) Replacement of labelling buﬀ ers (1 M NH4OAc and 1 M NaOAc) 
with de-ionised water also resulted in a signi cant increase of 
radiochemical yield from 78% to 98% without increasing the 
temperature to 37 C (entry 2 vs. 3). As a conse-quence, only 
[
64
Cu]Cu(OAc)2 solution without addition of buﬀ er solution or de-
ionised water was used in further experiments (entries 4–7). 
 
In all cases, radiochemical yields exceeded 95% at 37 C. High 
speci c activities of up to 16 GBq mmol 
1
 were achieved by lowering 
cryptand concentration to 0.25 nmol mL 
1
 while increasing 
radioactivity concentration to 4000 kBq mL 
1
 (entry 7). High speci c 
activities were obtained without the imple-mentation of puri cation 
steps. Radiolabeling of very low quantities of CryptTM (1.0 nmol to 
4.5 nmol) with up to 100 MBq of [
64
Cu]Cu(OAc)2 gave higher speci 
c activities of #45 GBq mmol 
1
 (corrected to recovered radioactivity 
a er solid-phase extraction puri cation as radiochemical yields 
decreased below 95%). The optimised reaction conditions for 
complexa-tion of [
64
Cu]Cu
2+
 by CryptTM are compatible with 
structural and functional integrity of delicate biopolymers like 
CryptTM-functionalised peptides and proteins as prospective 
targeting vectors for molecular imaging purposes. 
 
Based on previous density functional theory (DFT) calcula-tions, 
CryptTM has also been proposed to form complexes with trivalent 
cations like In(III), Y(III), and Ga(III).25 However, our radiolabelling 
experiments with [
68
Ga]Ga
3+
 obtained from a 
68
Ge/
68
Ga generator 
did not result in the formation of a stable [
68
Ga]Ga–CryptTM 
complex despite applying a variety of label-ling conditions as 
assessed by radio-TLC and radio-HPLC analysis (data not shown). 
 
The next set of experiments dealt with the investigation of 
[
64
Cu]Cu–CryptTM stability in vitro in direct comparison with 
literature-reported [
64
Cu]Cu–DiAmSar by means of challenge 
experiments involving chelators EDTA (log KCu–EDTA ¼ 18.5) and 
NOTA (log KCu–NOTA ¼ 21.6).
26 [
64
Cu]Cu–CryptTM and 
[
64
Cu]Cu– DiAmSar were challenged with competitive chelators 
EDTA and NOTA at stoichiometric ratios of 1 : 1 and 1 : 100 and 
were subsequently tested for trans-chelation of [
64
Cu]Cu
2+
 by radio-
TLC. Challenge experiments were performed at 25 C. The results are 
summarised in Table 2. 
 
In the case of [
64
Cu]Cu–CryptTM substantial trans-chelation was 
observed in the presence of chelators EDTA and NOTA when 
compared to [
64
Cu]Cu–DiAmSar. [
64
Cu]Cu–DiAmSar was inert 
towards trans-chelation with EDTA and NOTA over the entire 
course of the experiment (up 18 h). This is consistent with the 
reported high kinetic inertness of [
64
Cu]Cu–Sar complexes.22–24 
 
Challenge experiments of [
64
Cu]Cu–CryptTM with EDTA and 
NOTA gave higher rates of trans-chelation with EDTA for both 
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Table 1  Systematic optimisation of 64Cu-labelling conditions for CryptTM (time of radiolabelling was 60 min for each experiment)a 
       
  Concentration of Activity concentration Temperature Radiochemical Speci c activity 
Entry Buﬀ er CryptTM [nmol mL 1] cA [kBq mL 
1] [ C] yield [%] As [GBq mmol 
1] 
1 100 mL (A) 0.22 35 2 25 64   3 0.10 
 100 mL (B)     68   4 0.11 
 100 mL (C)   
0.0 
 51   2 0.08 
2 20 mL (B) 0.34 47 25 78   6 0.11 
     37 95   3 0.13 
3 20 mL (D) 0.34 72 
10 
25 98 0.20 
4 no buﬀ er added 0.46 200 37 >99* 0.44 
5 no buﬀ er added 0.46 1300 50 37 >99* 2.84 
6 no buﬀ er added 0.58 3684 526 37 > 95 6.36   0.91 
7 no buﬀ er added 0.25 4091 455 37 > 95 16.36   1.82  
a A 1 M ammonium acetate pH 5.0, B 1 M ammonium acetate pH 6.0, C 1 M sodium acetate pH 6.0, D de-ionized water, * 10 uL deionized water/ buﬀ er/PBS 
was added at the end of the reaction as result of solvent evaporation during radiolabeling procedure at 37 C.  
 
 
 
Table 2 Challenge experiments of [64Cu]Cu–CryptTM and [64Cu]Cu– 
DiAmSar with EDTA and NOTA (ratios refer to CryptTM/DiAmSar-to-EDTA 
or NOTA). Listed percentages refer to intact [64Cu]Cu–CryptTM or 
[64Cu]Cu–DiAmSar, respectively, as determined by radio-TLC  
(R
f,64Cu–EDTA 
¼
 
0.8;
 
R
f,64Cu–NOTA 
¼
 
0.5;
 
R
f,64Cu–CryptTM 
¼
 
0.0;
 
R
f,64Cu– 
DiAmSar 
¼
 
0.0) 
 
 EDTA   NOTA    EDTA   NOTA  
 challenge of challenge of  challenge of challenge of 
 [64Cu]Cu– [64Cu]Cu–  [64Cu]Cu– [64Cu]Cu– 
 CryptTM CryptTM  DiAmSar DiAmSar 
Time 
             
1 : 1 1 : 100 1 : 1 1 : 100 1 : 1 1 : 100 1 : 1 1 : 100 
            
10 min 46% 34%  74% 25%  100% 100%  100% 100% 
40 min 24% 18%  53% 12%  100% 100%  100% 100% 
18 h 11% 7%  9% 0%  100% 100%  100% 100% 
              
 
used stoichiometric ratios (1 : 1 and 1 : 100) within the rst 40 min of 
the experiment. This nding is surprising as Cu(II)–EDTA complex 
exhibits a thermodynamic complex stability constant three 
magnitudes lower compared to that of the Cu(II)–NOTA complex. 
Presumably, acyclic EDTA seems to be more exible in changing its 
three-dimensional conformation leading to kinet-ically more 
preferred transfer of [
64
Cu]Cu
2+
 from [
64
Cu]Cu– CryptTM to 
EDTA rather than from [
64
Cu]Cu–CryptTM to NOTA. However, a 
er 18 h, no intact [
64
Cu]Cu–CryptTM was detectable when a 1 : 100 
excess of NOTA was used for the challenge experiment. Under the 
same conditions, 7% of intact [
64
Cu]Cu– CryptTM was found a er 
18 h for the challenge experiment with EDTA. Notably, the rate of 
trans-chelation seems to be less aﬀ ected by the concentration of 
EDTA when compared with NOTA. Trans-chelation of [
64
Cu]Cu-
CrypTM with EDTA tends to occur rapidly within the rst 40 min, 
and signi cant trans-chelation was observed during this period of 
time. The amount of remaining intact complex a er 40 min was 
comparable (24% and 18%) for both tested stoichiometric ratios (1 : 
1 and 1 : 100, respectively). Rate of trans-chelation of [
64
Cu]Cu–
CryptTM in the presence of NOTA was more dependent on the ratio 
of the two chelators. At a 1 : 1 ratio of [
64
Cu]Cu–CryptTM to 
NOTA, 74% (10 min), 53% (40 min), and 9% (18 h) of intact 
[
64
Cu]Cu– CryptTM was detected. Signi cantly lower amounts of 
intact 
 
[
64
Cu]Cu–CryptTM were found at a 1 : 100 ratio between [
64
Cu] 
CryptTM and NOTA.  
These results suggest kinetically-driven trans-chelation of 
[
64
Cu]Cu–CryptTM with structurally exible acyclic EDTA chelator, 
whereas the driving force for trans-chelation of [
64
Cu] Cu–CryptTM 
with macrocyclic NOTA chelator seems to be the formation of 
thermodynamic more stable [
64
Cu]Cu–NOTA complex. 
 
Radiopharmacological evaluation of [
64
Cu]Cu–CryptTM in 
murine blood samples provided data on distribution pattern of 
radioactivity in blood cells, plasma proteins, and plasma at diﬀ erent 
time points (Fig. 3). Results in Fig. 3 revealed low binding of 
radioactivity ( 15%) on blood cells at all investigated time points (5, 
30, and 60 min). Increasing amounts of radio-activity were found in 
plasma protein fraction of murine blood which exceeded 70% of 
radioactivity in whole blood pool at 60 min. Consequently, 
radioactivity in plasma dropped over time, reaching 18% a er 60 min 
post injection (p.i.). Radio-TLC analysis of plasma fractions 
indicated intact [
64
Cu]Cu–CryptTM as administered intravenously at 
all points. The high plasma protein binding may be indicative of 
trans-chelation of [
64
Cu] Cu
2+
 to plasma proteins, and/or binding of 
intact [
64
Cu]Cu– CryptTM to plasma proteins. 
 
Radiopharmacological pro le of [
64
Cu]Cu–CryptTM was further 
elucidated with dynamic small animal PET imaging in  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Distribution of radioactivity in murine blood compartments after 
intravenous injection of [64Cu]Cu–CryptTM into normal mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
comparison to [
64
Cu]Cu–DiAmSar. In Fig. 4, representative PET 
images of [
64
Cu]Cu–CryptTM (Fig. 4A) and [
64
Cu]Cu–DiAmSar 
(Fig. 4B) a er 5, 15, and 60 min p.i. into EMT6 tumor-bearing 
BALB/c mice.  
A er injection of [
64
Cu]Cu–CryptTM and its initial distribu-tion 
phase, the majority of radioactivity was rapidly eliminated from the 
blood pool and cleared through the hepatobiliary elimination 
pathway. Radioactivity was also observed in the bladder during the 
perfusion phase. Over time, [
64
Cu]Cu– CryptTM demonstrated 
predominantly hepatobiliary excretion accompanied by an almost 
constant accumulation and reten-tion of radioactivity in liver tissue 
over time (Fig. 5). The determined distribution and clearance pattern 
in the case of [
64
Cu]Cu–CryptTM is consistent with the known 
tendency of pyridine derivatives to be subject of metabolism in liver 
cells by N-methyltransferases as well as monooxygenase 
cytochrome P450.27–30 
 
Moreover, the predominantly hepatobiliary excretion pathway of 
[
64
Cu]Cu–CryptTM also leads to exposure to liver enzyme 
superoxide dismutase as a potential site for trans-chelation of 
64
Cu
2+
 
resulting in accumulation and retention of radioactivity in the liver 
over time. This observation is also consistent with the results of the 
challenge experiments in this work (see Table 2) suggesting a 
substantial kinetic instability of [
64
Cu]Cu–CryptTM towards trans-
chelation. In contrast to [
64
Cu]Cu–CryptTM, [
64
Cu]Cu–DiAmSar 
was cleared almost exclusively through the kidneys, and the majority 
of radioac-tivity was found in the bladder a er 60 min p.i. The low 
uptake and rapid clearance of [
64
Cu]Cu–DiAmSar from the liver 
con rms high kinetic inertness of the complex towards trans-
chelation in vivo. However, the very fast elimination from blood 
system possibly denies de nite assessment of in vivo stability due to 
very short time of interaction with competitive endoge-nous ligands. 
The observed diﬀ erences in the biodistribution and elimination 
pattern of [
64
Cu]Cu–CryptTM and [
64
Cu]Cu– DiAmSar are in 
principle agreement with the determined  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Time-activity-curves of blood, kidneys, liver, bladder, tumour, and 
muscle after injection of [64Cu]Cu–CryptTM and [64Cu]Cu–DiA-mSar into 
EMT6-tumour bearing BALB/c mice.  
 
 
diﬀ erences in kinetic stability and lipophilicity of both complexes. 
Lipophilicity was determined according to the shake- ask method 
resulting in log P values of 0.3 and 3.7 at physiological pH of 7.4 for 
[
64
Cu]Cu–CryptTM and [
64
Cu]Cu– DiAmSar, respectively. 
 
Fig. 5 summarises all time-activity-curves for radioactivity 
uptake pro les from the heart (blood pool), liver, kidneys, bladder, 
tumour and muscle visualising diﬀ erent bio-distribution and 
clearance patterns a er injection of both 
64
Cu-labelled complexes. 
For [
64
Cu]Cu–CryptTM experiments we also calculated standardised 
uptake values (SUV) in EMT6-tumour tissue and muscle at which 
SUVtumour ¼ 0.40 0.03 (n ¼ 3) was signi cantly higher compared to 
SUVmuscle ¼ 0.16 0.02 (n ¼ 3) a er 60 min p.i. Injection of 
[
64
Cu]Cu–CryptTM led to a reten-tion of radioactivity in EMT6-
tumour tissue; however, overall uptake levels were comparable with 
previous experiments using [
64
Cu]Cu(OAc)2. This nding is 
indicative of non-speci c accu-mulation of radioactivity in EMT6 
tumours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 PET images (maximum intensity projection) of [64Cu]Cu– CryptTM 
(A) and for [64Cu]Cu–DiAmSar (B) at selected time points after single 
intravenous injection (5 MBq for each complex) into EMT-6 tumor-bearing 
BALB/c mice. 
 
Conclusions 
 
We have prepared and evaluated a novel 
64
Cu-labelled cryptand 
molecule ([
64
Cu]Cu–CryptTM). Radiopharmacological pro le of 
[
64
Cu]Cu–CryptTM was studied in comparison with [
64
Cu]Cu– 
DiAmSar as ‘gold standard’ for kinetically inert 
64
Cu-labelled 
cryptand molecules. Radiopharmacological evaluation of [
64
Cu]-
Cu–CryptTM revealed insuﬃcient kinetic stability which is 
consistent with the assumed unfavourable coordination mode of 
[
64
Cu]Cu
2+
 through two pyridyl and two amido donors as 
determined by crystal structure. However, the facile synthetic access 
to the novel cryptand CryptTM and related structures, and its 
favourable complex formation conditions using [
64
Cu]-Cu(OAc)2 
warrant further investigation of related CryptTM-type 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
molecules possessing a more favourable tri-pyridyl/tri-amine donor 
group set to allow formation of more kinetically inert 
64
Cu-
cryptates. 
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